Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 1

Conditions

Colorectal Neoplasms 439Stomach Neoplasms 248Carcinoma, Hepatocellular 246Rectal Neoplasms 211Colonic Neoplasms 204Pancreatic Neoplasms 172Esophageal Neoplasms 113Neoplasm Metastasis 75Liver Neoplasms 71Esophageal Squamous Cell Carcinoma 64Neoplasms 63Gastrointestinal Stromal Tumors 36Cholangiocarcinoma 36Gastrointestinal Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 25Gallbladder Neoplasms 25Adenocarcinoma Of Esophagus 24Biliary Tract Neoplasms 23Anus Neoplasms 22Adenocarcinoma 21Recurrence 19Bile Duct Neoplasms 19Breast Neoplasms 18Digestive System Neoplasms 17Lung Neoplasms 13Prostatic Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma 11Digestive System Diseases 10Peritoneal Neoplasms 9

Interventions

xaliproden 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Paresthesia × Gastrointestinal × Clear all
NCT01775449 2017-07-11

NEUROXAPOL

University Hospital, Clermont-Ferrand

Phase 3 Completed
80 enrolled
Gastrointestinal

Digestive System Neoplasms, Hyperalgesia, Paresthesia

NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

NCT00272051 2006-09-13

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Sanofi

Phase 3 Completed
620 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡